
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Proscia has released DermAI, a module on Proscia’s Concentriq Platform that leverages deep learning to pre-screen and classify skin biopsies. Proscia intends to submit DermAI to the FDA for review to use in clinical diagnosis.
To learn more, click






